Funding for Two Drug Combinations to Treat Type of Blood Cancer

Funding for two drug combinations to treat type of blood cancer

Pharmac has announced funding for two drug combinations to treat a kind of blood cancer. From May 1, people with chronic lymphocytic leukaemia, or...

Pharmac to fund two medicine combinations for chronic lymphocytic leukaemia

From May 1, people with chronic lymphocytic leukaemia will be able to access combination treatments of venetoclax with either ibrutinib or obinutuzumab.

Pharmac Update Blood Cancer Decision Due To Patient Feedback

This funding decision is another example of the new culture at Pharmac. The patient community used to picket outside Pharmac. Now, they’re in the room with Pharmac making decisions, says Associate Health Minister David Seymour.